HAVN Life Sciences Inc.

    HAVN Life Sciences Inc.

    CCSE:HAVN
    - -
    CAD
    - -
    - -
    2020 Y
    2021 Y
    2022 Y
    TTM
    Revenue per Share
    - -
    - -
    0.06
    0.11
    Basic EPS, GAAP
    -0.02
    -15.51
    -5.25
    -3.47
    Free Cash Flow per Basic Share
    -0.03
    -5.34
    -1.86
    -0.49
    Dividend per Share
    - -
    - -
    - -
    - -
    Book Value per Share
    0.85
    3.68
    0.62
    0.06
    Tangible Book Value per Share
    0.85
    2.86
    0.43
    0.06
    Basic Weighted Avg Shares
    2
    2
    4
    5
    Sales/Revenue/Turnover
    - -
    - -
    - -
    1
    Operating Margin (%)
    - -
    - -
    -3,548.44
    -703.25
    Depreciation Expense
    - -
    5
    1
    - -
    Net Income, GAAP
    - -
    -30
    -22
    -18
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    -8,117.81
    -3,141.49
    Working Capital
    2
    10
    2
    1
    LT Debt
    - -
    - -
    - -
    - -
    Total Equity
    2
    13
    3
    1
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    -402.36
    -274.69
    -275.25

    Capital Structure

    CAD

    •

    in mil. unless spec.
    Jul'23
    Oct'23
    Jan'23
    ST Debt
    1
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    6
    8
    15
    Market Capitalization
    9
    1
    1

    Working Capital

    CAD

    •

    in mil. unless spec.
    Jul'23
    Oct'23
    Jan'23
    Total Current Assets
    - -
    2
    1
    Cash, Cash Equivalents & STI
    - -
    - -
    - -
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    1
    1
    Total Current Liabilities
    1
    - -
    1
    Payables & Accruals
    1
    - -
    1
    ST Debt
    1
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    CAD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    -76.21%
    Free Cash Flow
    - -
    - -
    -23.69%
    Net Income, GAAP
    - -
    - -
    -26.13%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    CAD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    - -
    - -
    - -
    - -
    - -
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    CAD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    -0.37
    -3.35
    -5.14
    - -
    -15.51
    2022
    -22.63
    -1.42
    -0.52
    - -
    -5.25
    2023
    -27.05
    -0.41
    -0.07
    - -
    - -

    Quarterly Dividends Per Share

    CAD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2021
    - -
    - -
    - -
    - -
    - -
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • newsfilecorp.com

      HAVN Life to Present at Upcoming LD Micro Invitational XII

    • accesswire.com

      HAVN Life Sciences Inc. to Present at the Planet MicroCap Showcase 2022 in Las Vegas on Wednesday, May 4, 2022

    • accesswire.com

      HAVN Life Announces Supply and Distribution MOU with Mycrodose Therapeutics

    • accesswire.com

      HAVN Life Announces Distribution Deal with Horizon Grocery + Wellness

    • accesswire.com

      HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies

    • accesswire.com

      HAVN Life Harvests First Crop of Psilocybin Mushrooms at its Jamaica Facility

    • investorplace.com

      7 Stocks to Buy if You Think Alternative Therapies Are the Future

    • accesswire.com

      HAVN Life Signs Agreement to Enable Export of Psilocybin into Canada, the US and Europe

    • accesswire.com

      HAVN Life Signs Exclusive Supply Agreement With Cube Psytech

    • benzinga.com

      HAVN Life is Looking for a Safe Haven to Mental Health Through Psychedelic Medicine

    • accesswire.com

      HAVN Life Secures Production & Supply Agreement to Expand Retail Product Offerings

    • accesswire.com

      HAVN Life Enters into Agreement to Acquire Clinical Stage IP for Development of LSD-Derived API for Cluster Headaches

    • accesswire.com

      Havn Life CEO Tim Moore to Appear at Upcoming Q2 Investor SummitHavn Life CEO Tim Moore to Appear at Upcoming Q2 Investor Summit

    • accesswire.com

      Havn Life Signs Exclusive Supply Agreement with ATMA Journey Centers

    • accesswire.com

      Havn Labs Jamaica Facility Now Fully Operational

    • accesswire.com

      Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division

    • accesswire.com

      Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin with Jamaican Company Hypha Wellness

    • accesswire.com

      Havn Life CEO to Present at Zooming with LD, a Leading Platform for Microcap Companies